Skip to main content
TARS
NASDAQ Life Sciences

Tarsus Files Alkeus Financials: $564.8M IPR&D Charge and Going Concern Flag

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$70.82
Mkt Cap
$3.316B
52W Low
$53.89
52W High
$91.53
52W Position info
31% above low
Off High info
23% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

TARS sits 31% above its 52-week low of $53.89.

Summary

Tarsus filed the required financial statements for its Alkeus acquisition, revealing a $564.8 million IPR&D charge, a $23.6 million gain on consolidation, and going concern language for Alkeus.


Key Events · M&A and Partnerships · TARS

  • Alkeus Financials Filed

    Audited FY2025 and unaudited 9M 2026 financials for Alkeus filed as exhibits, showing accumulated deficit of $109.6M at June 30, 2026.

  • Going Concern Flag

    Alkeus's auditor (PwC) included substantial doubt language about Alkeus's ability to continue as a going concern, citing negative operating cash flows since inception.

  • $564.8M IPR&D Charge

    Tarsus will expense $564.8M of acquired in-process R&D immediately, as the gildeuretinol asset has no alternative future use.

  • Pro Forma Loss Impact

    Pro forma net loss for FY2025 is $696M, driven by the IPR&D write-off and $95.9M of contingent consideration liabilities.


Analysis · TARS · Life Sciences

This amendment to the September 10 8-K provides the first look at Alkeus's audited financials and the pro forma combined statements. The key new facts: Alkeus had an accumulated deficit of $109.6 million at June 30, 2026, and its auditor flagged substantial doubt about its ability to continue as a going concern. Tarsus will expense $564.8 million of acquired in-process R&D immediately, which will hit the income statement as a one-time charge. The pro forma net loss for the year ended December 31, 2025 balloons to $696 million, driven largely by that IPR&D write-off. This is the accounting reality behind the $450 million upfront deal — the acquired asset is being expensed, not capitalized, because it has no alternative future use.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TARS was trading at $70.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.3B. The 52-week trading range was $53.89 to $91.53. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TARS - Latest Insights

TARS
Nov 03, 2026, 4:08 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $74.00
Real-time Price: $81.22 info
Change: +$7.22 (+10%) info
Market Cap: $3.958B info
TARS
Nov 03, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $71.24
Real-time Price: $81.22 info
Change: +$9.98 (+14%) info
Market Cap: $3.958B info
TARS
Sep 10, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $81.12
Real-time Price: $81.22 info
Change: +$0.100 (+0.12%) info
Market Cap: $3.958B info
TARS
Aug 06, 2026, 7:25 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $58.27
Real-time Price: $81.22 info
Change: +$22.95 (+39%) info
Market Cap: $3.958B info
TARS
Aug 06, 2026, 7:23 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $58.27
Real-time Price: $81.22 info
Change: +$22.95 (+39%) info
Market Cap: $3.958B info